Summit Trail Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Summit Trail Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-169	Closed	-$1.79K	–	636
2023 Q4	$1.79K	Hold	169	–	–	﹤0.01%	559
2023 Q3	$3.35K	Hold	169	–	–	﹤0.01%	547
2023 Q2	$12.9K	Buy	+169	New	+$13.7K	﹤0.01%	541
2023 Q1	–	Sell	-169	Closed	-$16.5K	–	436
2022 Q4	$16.5K	Hold	169	–	–	﹤0.01%	402
2022 Q3	$44K	Hold	169	–	–	﹤0.01%	371
2022 Q2	$31K	Sell	169 -16	-9%	-$1.53K	﹤0.01%	380
2022 Q1	$18K	Hold	185	–	–	﹤0.01%	325
2021 Q4	$30K	Hold	185	–	–	﹤0.01%	293
2021 Q3	$51K	Buy	+185	New	+$56.6K	﹤0.01%	261
2019 Q1	–	Sell	-185	Closed	-$52K	–	128
2018 Q4	$52K	Hold	185	–	–	0.02%	104
2018 Q3	$89K	Hold	185	–	–	0.02%	275
2018 Q2	$84K	Hold	185	–	–	0.03%	232
2018 Q1	$125K	Hold	185	–	–	0.02%	392
2017 Q4	$128K	Buy	+185	New	+$133K	0.02%	560

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Summit Trail Advisors's TCRT Position: Q1 2024 in Review

Summit Trail Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 169 shares — an estimated $1.79K sold.

Summit Trail Advisors first reported a position in TCRT in Q4 2017 and held it in 14 quarters. The position peaked at $128K in Q4 2017. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Summit Trail Advisors reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Summit Trail Advisors sold 169 Alaunos Therapeutics shares in Q1 2024, an estimated $1.79K.
Summit Trail Advisors first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 14 quarters.
Summit Trail Advisors's Alaunos Therapeutics position peaked at $128K in Q4 2017.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Summit Trail Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.